Neutropenia News - LARVOL Sigma

Neutropenia	Welcome, Profile Billing Logout

«1 2...11 12 13 14 151617 18 19 20 21...635 636 »

|||||||||| cefepime hydrochloride / Generic mfg.
Recurrence of antibiotic resistant infections in children with cancer (Convention Center: Kamehameha Exhibit Hall - Level 1) - Apr 2, 2025 - Abstract #PAS2025PAS_2317;
Descriptive data for demographics, clinical presentation and initial outcome data are shown in Table 1. Recurrent cefepime-resistant infection occurred in 32/79 (41%) of FN episodes (95%CI 29-51%).

|||||||||| meropenem / Generic mfg.
Within-patient genetic relatedness of Pseudomonas aeruginosa strains from multiple body sites in hospitalized children with bloodstream infection (Convention Center: Kamehameha Exhibit Hall - Level 1) - Apr 2, 2025 - Abstract #PAS2025PAS_2315;
Six patients (67%) also grew Pa from other sites (5 perianal, 2 oral, 3 skin, 4 endotracheal tube or tracheal aspirate). We sequenced 557 Pa colonies (264 from blood, 293 from other sites).

|||||||||| GAME TIME!: ENHANCING HEALTHCARE STAFF KNOWLEDGE AND CONFIDENCE IN INFECTION PREVENTION THROUGH A (Convention Center: Kamehameha Exhibit Hall - Level 1) - Apr 2, 2025 - Abstract #PAS2025PAS_2255;
Knowledge scores increased by 24% (68.5 vs 92.3; P<.05). Seventy-seven percent (n=21/30) completed self-reported confidence questionnaires.

|||||||||| Impact of bronchioalveolar lavage on diagnostic yield and antimicrobial usage in pediatric oncology patients with febrile neutropenia (Convention Center: Kamehameha Exhibit Hall - Level 1) - Apr 2, 2025 - Abstract #PAS2025PAS_2063;
Exploratory analyses will evaluate association between clinical characteristics with BAL findings using parametric or non-parametric analyses, as appropriate for the data distribution. All statistical tests will be 2-sided with significance evaluated at the 5% level.

||||||||||  Zadaxin (thymalfasin) / SciClone
New trial:  Clinical study on the combination of target free drugs and thymus therapy for postoperative adjuvant therapy of hepatocellular carcinoma with high recurrence risk (EUDRACT) -  Apr 2, 2025
P=N/A, N=110, Not yet recruiting,  Sponsor: Kailuan General Hospital; Kailuan General Hospital

|||||||||| Journal: Can Bacillus paranthracis cause bacteremia in a T-ALL patient? WGS-based diagnosis. (Pubmed Central) - Apr 1, 2025
In a microbiology laboratory, the use of Whole Genome Sequencing (WGS) is important for diagnosing diseases, especially in immunocompromised patients. It will serve the management of these patients for infection control.

|||||||||| P2 data, Journal: Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. (Pubmed Central) - Apr 1, 2025
P2
Dual EGFR targeting without the chemotherapy backbone is worthy of further study. Trail Registration: ClinicalTrials.gov identifier: NCT01316757.

|||||||||| Clinical data, Journal: Evaluating the efficacy and impact of neutropenic diet in pediatric hematology patients: a longitudinal cohort study on adherence, clinical outcomes, and socioeconomic factors. (Pubmed Central) - Apr 1, 2025
Our study does not support the strict adherence to the neutropenic diet, as there is no evidence of reduced infections and the dietary adherence also imposes an undue financial burden on patients. Instead, focusing on the safe acquisition of food, food processing, and proper hand cleanliness will probably provide superior protection against infection.

|||||||||| Review, Journal: Methylmalonic acidemia with recurrent hemophagocytic lymphohistiocytosis: a case report and review of the literature. (Pubmed Central) - Apr 1, 2025
HLH is a rare and underrecognized hematologic emergency in methylmalonic acidemia, and its early diagnosis and treatment are critical. Serum ferritin may be a useful clinical biomarker in the diagnosis of HLH-associated attacks in methylmalonic acidemia.

|||||||||| Xolremdi (mavorixafor) / X4 Pharma, Norgine, Aphexda (motixafortide) / BioLineRx, Ayrmid
Review, Journal: Small molecule and peptide CXCR4 antagonists. A patent review from 2019 to 2024. (Pubmed Central) - Apr 1, 2025
In the last five years there has been significant advancement in CXCR4 antagonists as gauged by the FDA approval of two drugs. The search for second and third generation compounds will be the focus of future efforts with new uses and better properties which likely could come from some of the IP described herein.

|||||||||| Clinical, Journal: Extended clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients. A multicenter study by EBMT IEWP. (Pubmed Central) - Apr 1, 2025
One untransplanted patient died at the age of five years due to pancolitis and septicemia. All 31 other patients were reported to be alive and healthy at the last follow-up under supportive care.

|||||||||| Journal: Machine learning-based prediction reveals kinase MAP4K4 regulates neutrophil differentiation through phosphorylating apoptosis-related proteins. (Pubmed Central) - Mar 31, 2025
By modulating the phosphorylation level of proteins involved in cell apoptosis, such as STAT5A, MAP4K4 delicately regulates cell apoptosis during the process of neutrophil differentiation. Our work presents a novel regulatory mechanism in neutrophil differentiation and provides a robust prediction model that can be applied to other cellular differentiation processes.

|||||||||| oxaliplatin / Generic mfg., Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, docetaxel / Generic mfg.
P2 data, Journal: Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902). (Pubmed Central) - Mar 31, 2025
NAC with DOS for large type 3 or type 4 GC followed by gastrectomy demonstrated promising efficacy, high pathological response rates, and an acceptable toxicity profile. Further evaluation of long-term survival outcomes is ongoing.

|||||||||| Retrospective data, Journal: Bloodstream infections and colonization in hematopoietic stem cell transplant recipients at a South African center: A retrospective analysis. (Pubmed Central) - Mar 31, 2025
BSIs are a frequent and severe complication among HSCT recipients in South Africa, particularly in those receiving allogenic HSCT. Colonization with CRE significantly increases the risk of BSIs, underscoring the need for vigilant infection control and targeted antimicrobial strategies in this vulnerable population.

|||||||||| Journal: Prospective Validation of CAR-HEMATOTOX and a simplified version predict Survival in Patients with Large B-Cell Lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE study. (Pubmed Central) - Mar 31, 2025
P
In our prospective real-world study, we validated the ability of the HT score to predict ICAHT and survival. SimpleHT identified a population at very high risk with an impaired progression free and overall survival.

|||||||||| Journal: AI Enhanced explainable early prediction of blood culture positivity in neutropenic patients using clinical and hematologic parameters. (Pubmed Central) - Mar 30, 2025
In predicting gram-negative bacteria (GNB), the models demonstrated an accuracy and F1 score of 63%. To our knowledge, this is the first study to explore AI-powered early prediction of bacteremia in neutropenic sepsis patients in a South Asian population.

|||||||||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in Oncologic Children. (Pubmed Central) - Mar 30, 2025
To our knowledge, this is the first study to explore AI-powered early prediction of bacteremia in neutropenic sepsis patients in a South Asian population. CAZ-AVI could be used for treating GNB infections in oncologic pediatric patients.

|||||||||| Neulasta (pegfilgrastim) / Roche
Comparing Filgrastim and Pegfilgrastim for Primary Prophylaxis of Febrile Neutropenia in Early Breast Cancer: A real-world study (Hall B0) - Mar 29, 2025 - Abstract #ESMOBC2025ESMO_BC_735;
While no significant difference in FN rates was observed, pegfilgrastim was linked to higher rates of neutropenia and more frequent treatment delays and dose reductions, resulting in reduced dose-density. Since dose-density is crucial for treatment efficacy and FN risk remains a key consideration, further research is warranted to validate these findings.

|||||||||| Journal: A Rare Association of Celiac Disease and Aplastic Anemia. (Pubmed Central) - Mar 29, 2025
The pathogenesis of this association is not yet fully understood. The authors suggest that CD screening should be considered in patients with unexplained hematological abnormalities.

|||||||||| Journal: Stenotrophomonas maltophilia endogenous endophthalmitis in an immunocompetent eye in Australia. (Pubmed Central) - Mar 29, 2025
Despite the poor prognosis typically associated with endophthalmitis, this case resulted in a relatively good visual outcome (BCVA 6/18). This report highlights the necessity for further research to elucidate the epidemiology, risk factors, and optimal management strategies for this rare ocular condition.

|||||||||| Journal, Real-world evidence: Real-World Data on Outcome of Burkitt Lymphoma and Burkitt Leukemia Treated According to the GMALL B-ALL/NHL 2002 Protocol: A Tertiary Center Experience. (Pubmed Central) - Mar 29, 2025
These real-world findings underscore the efficacy of the GMALL protocol in BL management, with outcomes comparable to established regimens but coupled with high toxicity rates. Further comparative trials are essential to define the optimal therapeutic strategy.

|||||||||| Retrospective data, Journal: Cardioprotective Effect of Pegfilgrastim on Chemotherapy-induced Cardiotoxicity in Preoperative Chemotherapy for Breast Cancer. (Pubmed Central) - Mar 29, 2025
Further comparative trials are essential to define the optimal therapeutic strategy. Pegfilgrastim may reduce chemotherapy-induced cardiotoxicity in addition to preventing febrile neutropenia.

|||||||||| fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Journal: Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma. (Pubmed Central) - Mar 29, 2025
Prior ASCT and extramedullary disease represent adverse prognostic factors. Patients with a history of ASCT demonstrate limited peak CAR-T cell expansion.

|||||||||| Journal: Neutropenic sepsis and CMV-induced haemophagocytic lymphohistiocytosis in the postpartum period. (Pubmed Central) - Mar 29, 2025
Follow-up at 3 and 6 months post-admission showed that the patient remained clinically improved with no subsequent complications. This case highlights the challenging management of neutropenic sepsis complicated by HLH provoked by CMV in a postpartum woman.

|||||||||| Rinvoq (upadacitinib) / AbbVie
Retrospective data, Review, Journal, Adverse events: Insights into adverse events and safety profile of upadacitinib in the management of inflammatory bowel diseases - A meta-analysis of randomized controlled trials. (Pubmed Central) - Mar 29, 2025
However, the higher risks of neutropenia and CK elevation underscore the importance of monitoring. Further research is necessary to assess long-term safety, particularly regarding rare but serious events such as thromboembolism.

|||||||||| Journal: Neutrophil swarming is crucial for limiting oral mucosal infection by Candida albicans. (Pubmed Central) - Mar 29, 2025
Cortisone treatment similarly reduced neutrophil swarming behavior and BLT1 expression and delayed expression of epithelial cytokines and chemokines. Thus, swarm structures have an important function in preventing deep invasion by C. albicans within the oral mucosa and represent a mechanism for increased disease severity under immune deficient clinical settings.

|||||||||| Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Clinical data, Retrospective data, Journal: Treatment patterns and clinical outcomes in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer treated with chemotherapy: a large-scale data analysis using the Japanese claims database. (Pubmed Central) - Mar 28, 2025
Notably, the TTNTD shortens with successive treatments, and medical costs increase, intensifying the financial burden on patients. These findings indicate unmet needs for improved treatment options that enhance outcomes and reduce patient burden in advanced therapy lines.

|||||||||| Mifeprex (mifepristone) / Danco Laboratories
P2 data, Journal: A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. (Pubmed Central) - Mar 28, 2025
Preclinical data in TNBC and clinical data in other malignancies support further investigation of GR modulators. Future studies should incorporate biomarkers to select patients who benefit from GR inhibition.

|||||||||| hydroxyurea / Generic mfg.
Journal: Prevalence of Duffy Null and Its Impact on Hydroxyurea Dosing in Children With Sickle Cell Disease. (Pubmed Central) - Mar 28, 2025
We found a statistically significant difference (p = 0.006) in HU maximum tolerated dose (MTD) in patients with Duffy null phenotype compared with Duffy-positive individuals. Our study suggests that careful dose escalation is warranted in Duffy-null individuals.

|||||||||| Journal: Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy. (Pubmed Central) - Mar 28, 2025
GT did not affect the incidence of graft-versus-host disease or cytomegalovirus infection. This study is the first to include a control group and demonstrate a statistically significant association between GT therapy in the pre-engraftment period and shortened engraftment times in allo-HSCT recipients.

|||||||||| Journal: Sequential Treatment with Regorafenib and Trifluridine/Tipiracil (Pubmed Central) - Mar 28, 2025
This study did not show a statistically significant difference in OS with R-T versus T-R. Although limited by its retrospective nature, the study suggested R-T may be preferable to T-R given the observed reduction in neutropenia/myelosuppression-related treatments.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Retrospective data, Journal: Clinical Efficacy and Safety of Pembrolizumab Therapy for B-cell Lymphoma: A Systematic Review and Meta-analysis. (Pubmed Central) - Mar 28, 2025
Although limited by its retrospective nature, the study suggested R-T may be preferable to T-R given the observed reduction in neutropenia/myelosuppression-related treatments. The utilization of pembrolizumab, both as a monotherapy and in combination with other drugs, presented encouraging outcomes in patients with B-cell lymphoma.

|||||||||| cisplatin / Generic mfg., gemcitabine / Generic mfg.
Retrospective data, Journal: Visceral Adipose Predicts Prognosis and Toxicities in Locally Advanced Bladder Cancer Patients Treated With Adjuvant Gemcitabine Plus Cisplatin Chemotherapy. (Pubmed Central) - Mar 27, 2025
However, no significant difference was observed in terms of OS. Regarding chemotherapy-related AEs, patients in the high-VATI group exhibited a relatively lower incidence and severity of toxic reactions.

|||||||||| famotidine / Generic mfg., loratadine / Generic mfg., Neupogen (filgrastim) / Kyowa Kirin, Amgen
Journal: Effect of Prophylactic Dual Histamine Blockade on Filgrastim-Induced Bone Pain in Female Cancer Patients: Single Institutional Analysis. (Pubmed Central) - Mar 27, 2025
We propose that dualhistamine blockade may prove to be an effective option for prophylaxis of G-CSF-induced-bone-pain. Randomized control trials on larger and more diverse patient populations are required to reinforce the findings.

|||||||||| Preclinical, Journal: Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice. (Pubmed Central) - Mar 27, 2025
Randomized control trials on larger and more diverse patient populations are required to reinforce the findings. Our work strongly suggests that the Vox+anti-PD-1 antibody combination might significantly improve survival in patients with metastatic and treatment-refractory CRC by acting both on cancer cells and CD8+ T cells.

|||||||||| Biomarker, Retrospective data, Journal: Markedly elevated serum level of presepsin in agranulocytosis with hematologic malignancy: A potential (Pubmed Central) - Mar 27, 2025
Presepsin is a biomarker that can be assessed in patients undergoing GTX for agranulocytosis. A clinically significant increase in P-SEP levels before GTX may indicate ineffective GTX and an unfavorable prognosis.

|||||||||| Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
Journal: Letermovir use for cytomegalovirus prophylaxis following lung transplantation: A single-center review. (Pubmed Central) - Mar 27, 2025
CMV was detected in 14 LTRs following letermovir switch, with 2 discontinuing letermovir due to breakthrough CMV. Our findings support the use of letermovir for CMV prophylaxis in LTRs with possible benefits over valganciclovir, although a direct comparison is needed.

|||||||||| P1 data, Journal: Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study. (Pubmed Central) - Mar 27, 2025
The objective response rates for patients with measurable disease were 46.2%, 10.0%, 66.7%, and 25.0% in Parts E-H, respectively. A recommended Phase 2 dose was not established for Parts E, G, and H at the dose levels evaluated, and was determined to be 150 mg Q12H in Part F. Overall, our results demonstrate safety profiles consistent with those previously established for abemaciclib and provide preliminary data for these combination therapies in the treatment of HR+, HER2- or HER2+ MBC.

|||||||||| Journal, Adverse events: Linezolid Related Adverse Effects in Different Populations: A Practical Review. (Pubmed Central) - Mar 27, 2025
Patients with multidrug-resistant tuberculosis and bone infections are at an increased risk for anemia, peripheral neuropathy, and optic neuropathy. Additionally, lactic acidosis and hyponatremia can occur at any stage during treatment.

|||||||||| Journal: Utilizing Viral Metagenomics to Characterize Pathogenic and Commensal Viruses in Pediatric Patients with Febrile Neutropenia. (Pubmed Central) - Mar 27, 2025
However, due to the complex nature of this disease, more studies are necessary to evaluate their causal relationship. The results obtained in our study may serve to improve patient treatment and ensure adequate management.

|||||||||| irinotecan / Generic mfg.
Review, Journal: Managing Irinotecan-Induced Diarrhea: A Comprehensive Review of Therapeutic Interventions in Cancer Treatment. (Pubmed Central) - Mar 27, 2025
This review encompasses an exploration of chemical formulations, the application of traditional Chinese medicine, and the advent of innovative drug delivery systems. It is anticipated that this article will serve as a valuable resource for both novice researchers in the realm of irinotecan chemotherapy and for those who are well-versed in the field, including experts and practicing clinicians.

|||||||||| Retrospective data, Journal: The Role of Initial Neutropenia and Neutrophil Dynamics in Personalizing Chemotherapy for Platinum-Resistant Ovarian Cancer. (Pubmed Central) - Mar 27, 2025
Baseline neutropenia is a significant prognostic marker in PROC, correlating with improved tumor response and survival outcomes despite increased hematological toxicities. These findings support incorporating baseline ANC into treatment personalization strategies for PROC.

|||||||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead, irinotecan / Generic mfg.
Review, Journal: Influence of the UGT1A1 gene polymorphism on treatment with sacituzumab govitecan. Narrative review. (Pubmed Central) - Mar 27, 2025
Despite the clear relationship between UGT1A1 polymorphisms and sacituzumab-govitecan toxicity, the review suggests that there is insufficient consensus on the need for systematic genetic screening. However, the findings indicate that such screening could be useful for identifying patients at risk and personalizing sacituzumab govitecan therapy.

|||||||||| Journal: Update on the Treatment of Chronic Spontaneous Urticaria. (Pubmed Central) - Mar 27, 2025
About 70% of patients with antihistamine-refractory CSU do not reach complete control with omalizumab, the second-line treatment...Several emerging treatments can address these unmet needs including Bruton tyrosine kinase inhibitors, e.g., remibrutinib and rilzabrutinib; anti-KIT monoclonal antibodies, e.g., barzolvolimab; and anti-cytokine therapies, e.g., dupilumab...The most common adverse events were injection site reactions for dupilumab (12%), respiratory tract infections (11%), headache (6%), and petechiae (4%) for remibrutinib and changes in hair color (14%), neutropenia / decreased neutrophil count (9%) and skin hypopigmentation (1%) for barzolvolimab. This review provides an update on the current state of development of treatments for CSU.

|||||||||| Neulasta (pegfilgrastim) / Roche
Clinical guideline, Retrospective data, Review, Journal: Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022. (Pubmed Central) - Mar 27, 2025
Further research should identify the specific subgroups that most benefit from dose-dense regimens. More data are needed on the impact on QOL.

|||||||||| Review, Journal: Macrophage activation syndrome in Kawasaki disease: a literature review of Korean studies. (Pubmed Central) - Mar 26, 2025
In actual practice, MAS may be underrecognized in patients with KD. Clinical suspicion is paramount for early diagnosis and timely treatment.

|||||||||| Inokai (orelabrutinib) / InnoCare, Biogen, Rituxan (rituximab) / Roche
Retrospective data, Journal: Clinical study of orelabrutinib combined with R-CHOP regimen for newly diagnosed high-risk non-GCB diffuse large B-cell lymphoma with extranodal involvement (Pubmed Central) - Mar 26, 2025
Serious adverse events included febrile neutropenia, pneumonia, and atrial flutter, but no treatment-related deaths. In patients with high-risk non-GCB DLBCL and extranodal involvement, the combination of orelabrutinib with R-CHOP regimen had good efficacy and manageable toxicity.

|||||||||| Venclexta (venetoclax) / Roche, AbbVie
Retrospective data, Journal: Efficacy and safety analysis of venetoclax in combination with multidrug chemotherapy in patients with newly diagnosed acute leukemia of ambiguous lineage (Pubmed Central) - Mar 26, 2025
All patients recovered hematopoietic function after the initial induction therapy, with no fatal hemorrhage, tumor lysis syndrome, neurological adverse events, or grade 3 or higher organ toxicity, excluding preexisting conditions. Venetoclax in combination with multidrug chemotherapy was effective and associated with tolerable adverse reactions in patients with newly diagnosed ALAL.

|||||||||| Retrospective data, Journal, Real-world evidence: Real-World Data to Assess the Proportion of Patients Admitted for Febrile Neutropenia That Could Be Considered at Low Risk: The Experience of the Centre Hospitalier Universitaire de Qu (Pubmed Central) - Mar 26, 2025
In contrast, among patients who did not meet the eligibility criteria for outpatient treatment, 44.7% (46/103) experienced favorable outcomes during their hospitalization. These data highlight the importance of patient selection for outpatient care.

|||||||||| Review, Journal: Mortality-Related Risk Factors in Patients with Hematologic Neoplasm Admitted to the Intensive Care Unit: A Systematic Review. (Pubmed Central) - Mar 26, 2025
Mortality among hematooncology ICU patients is associated with IMV, vasopressor support, pulmonary involvement, sepsis, neutropenia, severe respiratory failure, ICU readmission, and late admission. Identifying and managing these factors in a timely manner can improve survival and the quality of care.



	Diseases Companies Products Productz Mechanisms of Action Sites